Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. Today, we go deep on the drug-pricing deal Pfizer has struck with President Trump, hear from an expert on leucovorin, and more.
Pfizer and Trump strike drug-pricing deal
President Trump yesterday announced that Pfizer has agreed to offer lower prices on its drugs to the Medicaid program, among other steps, and will also price new drugs “at parity” with those in other countries. In addition, Trump announced that the administration would launch a TrumpRx.gov drug purchasing platform. You can read all about the agreement here.
